FIELD: medicine.
SUBSTANCE: method for evaluating severity of preeclampsia involves examining peripheral venous blood plasma in pregnant women carrying male fetuses, after their 20 weeks of pregnancy for the foetal DNA concentration in peripheral venous blood plasma, and if the concentration is less than 0.9 ng/ml, uncomplicated gestation course is predicted; the concentration of foetal genetic material within 1.8 to 2.6 ng/ml enables predicting moderate preeclampsia, while the concentration of 2.6 ng/mg and more shows severe preeclampsia.
EFFECT: higher reliability of evaluating the severity of preeclampsia in the pregnant women by the level of disturbed placentation.
6 cl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREECLAMPSIA SEVERITY DIAGNOSTICS BASED ON EVALUATION OF DNA-RECOGNIZING DAI-1 RECEPTORS EXPRESSION IN PLACENTAL TISSUE | 2017 |
|
RU2641029C1 |
| METHOD OF DIAGNOSTICS OF PREECLAMPSIA ON THE GESTATION UP TO 34 WEEK BY EVALUATION OF LEVELS OF ANG (1-8) VASOCONSTRICTOR AND ANG (1-7) VASODILATOR | 2017 |
|
RU2663456C1 |
| METHOD FOR PREDICTION OF PREECLAMPSIA IN PREGNANT WOMEN WITH GESTATIONAL DIABETES MELLITUS | 2020 |
|
RU2740852C1 |
| METHOD FOR PREDICTION OF RISK OF PREECLAMPSIA BY COMBINATION OF CYTOKINE GENES | 2014 |
|
RU2568891C1 |
| DIAGNOSTIC TECHNIQUE FOR SEVERE PREECLAMPSIA IN PREGNANT WOMEN | 2019 |
|
RU2730958C1 |
| METHOD FOR EARLY DIAGNOSTICS OF SEX IN A CHILD UNDER FUTURE DELIVERY | 2006 |
|
RU2317334C1 |
| PREDICTION OF PREECLAMPSIA BASED ON DETERMINING EXTRACELLULAR FETAL DNA IN MATERNAL BLOOD WHEN SCREENING THE FIRST TRIMESTER OF PREGNANCY | 2019 |
|
RU2697845C1 |
| METHOD FOR FORMING RISK GROUP OF PRE-ECLAMPSIA | 2021 |
|
RU2762204C1 |
| METHOD FOR PREDICTION OF PLACENTAL INSUFFICIENCY IN SECOND TRIMESTER OF PREGNANCY | 2014 |
|
RU2554827C1 |
| METHOD FOR PREDICTING THE RISK OF DEVELOPMENT OF PREECLAMPSIA IN PREGNANT WOMEN WITH FETAL GROWTH RESTRICTION SYNDROME | 2021 |
|
RU2754956C1 |
